Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Pogoda, Katarzyna ^a   Niwińska, Anna ^a   Murawska, Magdalena ^b   Pieńkowski, Tadeusz ^c  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Medical Center of Postgraduate Education   (Poland)

Author keywords

Brain metastases; Metastatic breast cancer; Prognostic factor; Recurrence pattern; Triple negative breast cancer; Tumor size

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; NAVELBINE; PLATINUM; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC THERAPY; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MASTECTOMY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY; RECEPTORS, CELL SURFACE; RISK FACTORS; YOUNG ADULT;

EID: 84871720054     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0388-4     Document Type: Article

References (35)

1. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784-95.
2. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736-47.
3. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5:5-23.
4. Ghosn M, Hajj C, Kattan J, et al. Triple-negative breast cancer in Lebanon: a case series. Oncologist. 2011;16:1552-6.
5. Hamm C, El-Masri M, Poliquin G, et al. A single-centre chart review exploring the adjusted association between breast cancer phenotype and prognosis. Curr Oncol. 2011;18:191-6.
6. Heitz F, Harter P, Traut A, Lueck HJ, Beutel B, du Boi A. Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors. J Clin Oncol. 2008;26(15 suppl) (abstract 1010).
7. Kaplan HG, Malmgren JA. Impact of triple negative phenotype on breast cancer prognosis. Breast J. 2008;14:456-63.
8. Lee JA, Kim KI, Bae JW, Jung YH, An H, Lee ES, Korean Breast Cancer Society. Triple negative breast cancer in Korea - distinct biology with different impact of prognostic factors on survival. Breast Cancer Res Treat. 2010;123:177-87.
9. Dent R, Trudeau M, Pritchard KL, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429-34.
10. Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer? Breast Cancer. 2008;15:303-8.
11. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329-34.
12. Mersin H, Yildirim E, Berberoglu U, Gulben K. The prognostic importance of triple negative breast carcinoma. Breast. 2008;17:341-6.
13. Liedke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275-81.
14. Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012;. doi: 10.1002/cncr.27581.
15. Dawood S, Broglio K, Esteva FJ, et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol. 2009;20:621-7.
16. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer. Cancer. 2008;113:1638-45.
17. Anders CK, Deal AM, Miller CR, et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer. 2011;117:1602-11.
18. Niwińska A, Murawska M, Pogoda K. Breast cancer brain metastasis: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole brain radiotherapy (WBRT). Ann Oncol. 2010;21:942-8.
19. Wang S, Yang H, Tong F, et al. Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer. Gan To Kagaku Ryoho. 2009;36:255-8.
20. Jung SY, Rosenzweig M, Sereika SM, Linkov F, Brufsky A, Weissfeld JL. Factors associated with mortality after breast cancer metastasis. Cancer Causes Control. 2012;23:103-12.
21. National Comprehensive Cancer Network (NCCN). Breast Cancer 1:BINV-8, BINV-K. In: NCCN clinical practice guidelines in oncology. 2012. http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf. Accessed 26 June 2012.
22. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA. 2006;295:2492-501.
23. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7:4-13.
24. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28:3271-7.
25. Alarcon-Rozas AE, Cueva MR, Galarreta J et al. Features of recurrence of triple-negative (TN), non-metastatic breast cancer (NMBC) patients: A single institution study. J Clin Oncol. 2011;29(suppl 27) (abstract 180).
26. Ovcaricek T, Frkovic SG, Matos E, Mozina B, Borstnar S. Triple negative breast cancer - prognostic factors and survival. Radiol Oncol. 2011;45:46-52.
27. Park YH, Chang MH, Lee S, et al. Heterogeneity of triple negative breast cancer (TNBC): TNBC might be divided into two or more subgroups by clinicopathologic findings. Cancer Res. 2009;69(suppl 24) (abstract 6032).
28. Niwińska A, Olszewski W, Murawska M, Pogoda K. Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes. J Neurooncol. 2011;105:547-53.
29. Dawood S, Lei X, Litton JK, et al. Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer. 2012;. doi: 10.1002/cncr.27434.
30. Kaplan HG, Malmgren JA, Atwood M. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J. 2009;15:454-60.
31. Amar S, McCullough AE, Tan W, et al. Prognosis and outcome of small (≤1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status. Oncologist. 2010;15:1043-9.
32. Bulut N, Aksoy S, Dizdar O, et al. Demographic and clinic-pathological characteristics in patients with triple-negative and non triple-negative breast cancer. Med Oncol. 2011;suppl 1:75-9.
33. Hernandez-Aya LF, Chavez-MacGregor M, et al. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol. 2011;29:26282634.
34. Park YH, Lee SJ, Cho EY, et al. Clinical relevance of TNM staging system according to breast cancer subtypes. Ann Oncol. 2011;22:1554-60.
35. Kassam F, Enright K, Dent R, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 2009;9:29-33.